EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway Programme

Virtual Event, Worldwide

11 - 12 February 2025

Scientific Programme

Tuesday 11th February 2025

Listed times are in Central European Time (CET)

13:00 WELCOME TO DAY ONE

Chair: Marco Hofmann

13:10 OPENING KEYNOTE LECTURE

Piro Lito
Memorial Sloan Kettering Cancer Center, USA
'A 'new' old approach to inactivate RAS'

Q&A 13:40-13:55

13:55 **Miriam Molina Arcas**
Francis Crick Institute, UK
'Rational approaches to combine KRAS inhibitors and immunotherapies in lung cancer'

Q&A 14:15-14:25

14:25 **Saptaparna Mukherjee**
Francis Crick Institute, UK
Proffered Paper 1: 'MYC and KRASG12C Cooperation Drives Immune-Evasive Tumour Progression in Lung Adenocarcinoma'

Q&A 14:35-14:40

14:40 REFRESHMENT BREAK

Chair: Anna Obenauf

15:00 **Sandra Misale**
John Hopkins University, USA
'Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma'

Q&A 15:20-15:30

15:30 **Robert Kortum**
Uniformed Services University, USA
Proffered Paper 2: 'SOS1 inhibition enhances the efficacy of and delays resistance to oncogene-targeted therapies in lung adenocarcinoma'

Q&A 15:40-15:45

15:45 **Mallika Singh**
Revolution Medicines, USA
'Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors'

Q&A 16:05-16:15

16:15 POSTER SPOTLIGHTS

16:25 TRANSITION BREAK

16:35 VIRTUAL POSTER SESSION ONE
Scheduled to end at 17:35 CET

Wednesday 12th February 2025

Listed times are in Central European Time (CET)

12:30 VIRTUAL POSTER SESSION TWO
Scheduled to end at 13:30 CET

14:00 WELCOME TO DAY TWO

Chair: Chiara Ambrogio

14:05 **Marco Hofmann**
Boehringer Ingelheim, Austria
'Targeting the RAS Signaling Pathway: Inhibitors and Mechanisms of Resistance'

Q&A 14:25-14:35

14:35 **Alberto Bardelli**
University of Torino, Italy
'Adaptive cancer mutability in response to targeted therapies'

Q&A 14:55-15:05

15:05 **Christian Umkehrer**
Boehringer Ingelheim, Austria
Proffered Paper 3: 'Dissecting the clonal evolution of resistance to KRAS inhibitors through genetic barcoding and scRNAseq'

Q&A 15:15-15:20

15:20 REFRESHMENT BREAK

Chair: René Bernards

15:40 **Marina Pasca di Magliano**
University of Michigan Medicine School, USA
'Oncogenic KRAS mediated regulation of the pancreatic cancer microenvironment'

Q&A 16:00-16:10

16:10 **Gonzalo Aizpurua**
Spanish National Cancer Research Centre, Spain
Proffered Paper 4: 'Identifying RAF1 degraders as a therapeutic approach in KRAS-driven lung tumors'

Q&A 16:20-16:25

16:25 CLOSING KEYNOTE LECTURE
Colin Lindsay
Manchester Cancer Research Centre, UK
'Bedside to bench to bedside again: leveraging KRAS precision medicine for optimum clinical benefit'

Q&A 16:55-17:10

17:10 DISCUSSION SESSION

René Bernards, Anna Obenauf, Marco Hofmann & Chiara Ambrogio

'New challenges for old therapeutic targets: What's next?'

17:50 SUMMARY AND CLOSE